Navigation Links
Micromet Expands Committed Equity Financing Facility to $75 Million
Date:12/2/2008

securities, nor shall there be any sale of these securities in any state which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, Maryland and Munich, Germany. The Company is developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company uses its proprietary BiTE(R) antibody platform to create a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease-related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration with MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT 110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a conventional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet has licensed a fourth c
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Micromet Announces Changes in Management Team
2. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
3. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
11. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/19/2014)... -- PCI is pleased to announce it has acquired ... provider of Clinical Trial Services and Temperature Controlled ... in the United Kingdom ... in the UK/EU to support global investigational studies ... distribution capacity, as well as consultative services for ...
(Date:9/18/2014)... 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... of the underwriters, option to purchase 675,000 additional ... company,s previously announced public offering of 4,500,000 shares ... being offered by Aratana Therapeutics.  With the exercise ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
(Date:9/20/2014)... The Arizona Advanced Manufacturing Institute ... Manufacturing Day by opening its doors to the community. ... manufacturing labs will be offered between 10 a.m. and ... and Dobson campus (1833 W. Southern Ave, Mesa, AZ ... The AzAMI at MCC was established in the fall ...
(Date:9/19/2014)... Columbus, OH (PRWEB) September 20, 2014 ... Philadelphia Court of Common Pleas where a meeting took ... Risperdal side-effects complaints pending in the court’s mass ... scheduled to meet this past week at the Complex ... complaints are consolidated for pretrial proceedings. The Risperdal lawsuits ...
(Date:9/19/2014)... BearCom, a nationwide provider of wireless ... role played by instant, one-to-one and one-to-many communications ... , “In healthcare, speed of information flow ... emergency situations, can save precious seconds that can ... Hugh Johnston, Product & Purchasing Manager at BearCom. ...
(Date:9/19/2014)... working with The Melanoma Genetics Consortium, GenoMEL, an international ... Journal of the National Cancer Institute that ... "For the first time, we have established that the ... part in the risk of developing melanoma," said lead ... Medicine at the University of Leeds (UK). , ...
(Date:9/19/2014)... News) -- Your brain structure could help predict how willing ... Researchers at Yale University found those with greater volume ... cortex may be more likely to engage in risky behavior ... The study, funded by the U.S. National Institute on Aging, ... in the Northeast. The researchers sought to determine how brain ...
Breaking Medicine News(10 mins):Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4Health News:Melanoma risk found to have genetic determinant 2Health News:Brain Structure Might Help Predict Risky Behavior 2
... bundles, scientists say , , WEDNESDAY, April 15 (HealthDay News) ... in certain neural pathways of the brain to the ... finding could lead to a better understanding of the ... and coordination that characterizes this difficult-to-diagnose disorder -- also ...
... MD, April 14, 2009 -- Sleep is such an essential ... of our lives doing it -- some more successfully than ... United States and are a major cause of disease and ... risk of heart attack, stroke, hypertension, obesity, depression, and accidents. ...
... with 100% of Updated Interoperability RequirementsTAMPA, Fla., April ... provider of electronic health records, today announced that ... has approved Sage,s product, Sage Intergy EHR, ... EHR , additionally certified for Child ...
... Harvard Business School recently completed a case study ... a private nonprofit organization that helps children and families ... a national leader in the field of children,s behavioral ... Allen Grossman, Catherine Ross of the HBS Global Research ...
... AIDS for years after initial infection by HIV have ... One component of this remarkable resistance comes from an ... genes that help the immune system recognize and fight ... the Emory Vaccine Center studying HIV-infected people with particularly ...
... minimally invasive surgical approach to treat stomach cancer has ... a preferable treatment for some patients. , A new ... (MSKCC) compares traditional "open" surgery to remove the stomach ... which the surgeon removes the stomach while guided by ...
Cached Medicine News:Health News:Brain Scans Reveal Secrets of 'Writer's Cramp' 2Health News:New way to analyze sleep disorders 2Health News:New way to analyze sleep disorders 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 2Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 3Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 4Health News:HIV handicaps itself to escape immune system pressure 2Health News:New minimally invasive surgery option for patients with stomach cancer 2
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
... is a supportive .035" guide wire compatible stent system ... lengths of 18 mm, 28 mm, 38 mm and ... in 12 and 16 mm lengths. The 4.0 ... Two "diameter specific" OMNILINK® stents were developed - one ...
... particular challenge in transseptal left heart catheterization ... be exchanged for a sheath with an ... position. Traditionally, such an exchange has required ... patient. Biosense Webster has overcome this problem ...
... Jude Medical's line of guiding introducers ... RAMP, and 2 piece steerable, all ... catheters when the varying curves and ... physician technique. St. Jude Medical guiding ...
Medicine Products: